When you’re making content, branding is very important. If you use Filmora to edit videos or make other content, adding the Filmora logo PNG to your designs can be a smart way to show that you work ...

Canaccord downgraded Intra-Cellular (ITCI) to Hold from Buy with a price target of $132, up from $119, after Johnson & Johnson (JNJ) agreed to acquire all of the company’s outstanding shares for ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Needham analyst Ami Fadia downgraded Intra-Cellular (ITCI) to Hold from Buy without a price target after Johnson & Johnson said will acquire all outstanding shares of Intra-Cellular for a payment ...

For the first time in almost 20 years, Walmart has a new logo. The international retailer describes it as a “a comprehensive brand refresh,” but the online world hasn’t been quite so kind to ...

Jan 12 (Reuters) - Drug maker Johnson & Johnson (JNJ.N), opens new tab is exploring a bid to acquire Intra-Cellular Therapies (ITCI.O), opens new tab, a biopharmaceutical company, Bloomberg News ...

Johnson & Johnson will acquire Intra-Cellular for $132 per share in cash, a 39 percent premium over Intra-Cellular's Friday closing price of $94.87. Following the announcement, shares of both ...

Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will ...

Intra-Cellular Therapies (ITCI) shares soared 14.9% in the last trading session to close at $94.87. The move was backed by solid volume with far more shares changing hands than in a normal session.

Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said Monday ...